Clinical Trial Update: Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Cetuximab beta in combination with the PRaG regimen for EGFR-positive advanced refractory solid tumors; the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Cetuximab beta (cetuximab beta)
• PRaG regimen

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Advanced Refractory Solid Tumors | Phase 2 | Status: NOT_YET_RECRUITING